KR20200058929A - A composition comprising an extract of combined natural products for treating and preventing Male Infertility - Google Patents
A composition comprising an extract of combined natural products for treating and preventing Male Infertility Download PDFInfo
- Publication number
- KR20200058929A KR20200058929A KR1020180143651A KR20180143651A KR20200058929A KR 20200058929 A KR20200058929 A KR 20200058929A KR 1020180143651 A KR1020180143651 A KR 1020180143651A KR 20180143651 A KR20180143651 A KR 20180143651A KR 20200058929 A KR20200058929 A KR 20200058929A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- sperm
- fructus
- ginseng
- Prior art date
Links
- 208000007466 Male Infertility Diseases 0.000 title claims abstract description 27
- 239000000284 extract Substances 0.000 title claims description 50
- 239000000203 mixture Substances 0.000 title claims description 25
- 229930014626 natural product Natural products 0.000 title description 13
- 210000000582 semen Anatomy 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 208000000509 infertility Diseases 0.000 claims abstract description 5
- 230000036512 infertility Effects 0.000 claims abstract description 5
- 231100000535 infertility Toxicity 0.000 claims abstract description 5
- 241000208340 Araliaceae Species 0.000 claims description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 16
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 16
- 235000008434 ginseng Nutrition 0.000 claims description 16
- 230000036541 health Effects 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 235000013376 functional food Nutrition 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 8
- 244000269722 Thea sinensis Species 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 6
- 235000017803 cinnamon Nutrition 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 5
- 241001558929 Sclerotium <basidiomycota> Species 0.000 claims description 5
- 239000008989 cinnamomi cortex Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 244000241838 Lycium barbarum Species 0.000 claims description 4
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 235000015468 Lycium chinense Nutrition 0.000 claims description 3
- 206010003883 azoospermia Diseases 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000002689 soil Substances 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 240000004385 Centaurea cyanus Species 0.000 claims 1
- 235000005940 Centaurea cyanus Nutrition 0.000 claims 1
- 241000282320 Panthera leo Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000004899 motility Effects 0.000 abstract description 4
- 241000411851 herbal medicine Species 0.000 abstract description 3
- 208000021267 infertility disease Diseases 0.000 abstract description 2
- 231100000688 decreased sperm quality Toxicity 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000019100 sperm motility Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000004720 fertilization Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 235000013616 tea Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000209020 Cornus Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 208000005725 Vohwinkel syndrome Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241001310492 Pectis angustifolia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- -1 external preparation Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000001368 germline stem cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical group C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 231100000527 sperm abnormality Toxicity 0.000 description 1
- 230000009303 sperm storage Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 남성 불임증의 예방 및 치료용 약학 조성물 및 건강기능식품에 관한 것으로, 상세하게는 정자의 활동성을 개선하고, 동시에 정자수를 증가시킴으로서 남성 불임증을 치료 및 예방하는 효과를 가진 복합 천연물의 추출물을 유효성분으로 포함하는 것을 특징으로 하는 약학 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition and a health functional food for the prevention and treatment of male infertility, and in detail, to improve the activity of sperm and increase the number of sperm at the same time, extract of a complex natural product having the effect of treating and preventing male infertility It relates to a pharmaceutical composition characterized in that it comprises as an active ingredient.
남성 불임이란 적어도 1년 이상 정상적인 성생활을 하였음에도 남성 쪽 원인으로 아이를 출산하지 못하는 상태이다. 결혼한 부부의 15% 정도가 불임이고, 이 중 남성 쪽 원인은 40~60%로 여겨진다. 남성 불임은 남성 호르몬을 포함한 호르몬 문제, 독성물질 노출이나 감염 및 외상으로 고환에 생긴 문제, 정자의 문제, 정상적인 정자라 하더라도 배출되는 길이 비정상적인 경우 등의 이유로 발생할 수 있다.Male infertility is a condition in which a child cannot give birth due to male causes even though he has had a normal sex life for at least one year. About 15% of married couples are infertile, and the male cause is considered to be 40-60%. Male infertility can be caused by hormonal problems, including testosterone, problems with testicles due to exposure or infection or trauma toxins, sperm problems, or even abnormal sperm discharge.
현재까지 불임의 치료에 많은 발전이 있었지만 정자의 운동성을 향상시키는 남성불임치료제는 부재 상태이며, 임신을 향상시킬 수 있는 약물의 개발도 매우 저조한 편이다. 종래 기술에서는 내과적, 외과적 치료에도 불구하고 원인을 알 수 없이 정액의 질이 나쁜 남성에서 정액의 질을 향상시킬 수 있는 약물로 현재 L-carnitine이 사용되고 있으나 뚜렷한 효능을 보이지 못하고 있다.Although many advances have been made in the treatment of infertility to date, male infertility treatments that improve sperm motility are absent, and the development of drugs that can improve pregnancy is also very low. In the prior art, despite medical and surgical treatment, L-carnitine is currently used as a drug capable of improving the quality of semen in men with poor quality of semen without knowing the cause, but it does not show a distinct effect.
정자활력(sperm motility)은 정자의 생존성에 대한 훌륭한 지표(indicator)가 될 수 있으며(Noran 등, 1998), 정액품질을 평가하는 공통의 지표에는 정자농도, 기형정자율, 생사정자비율, 정액량, pH, 정자의 초기활력 및 정자의 집단운동(mass movement)등이 있다.Sperm motility can be a good indicator of sperm viability (Noran et al., 1998). Common indicators for evaluating sperm quality include sperm concentration, malformed sperm rate, live sperm rate, and semen amount. , pH, sperm initial vitality, and sperm mass movement.
한편, 인간을 포함한 포유동물에 있어서 생식세포인 정자는 남성측 유전정보를 다음 세대에 전달하는 중요한 매개체로서 정자를 생산하는 일련의 복합적인 과정을 포함하는 정자형성과정(spermatogenesis)은 종의 보존과 유전적 다양성에 있어서 필수적인 과정이다. 이같이 복합적이고 생산적인 정자형성과정에 있어서 생식선줄기세포인 정원줄기세포는 남성의 생애전반에 걸쳐서 정자형성과정을 유지시키는 중요한 기본세포로 인식되고 있다. 특히 정자생산에 직접적인 역할을 하는 정원줄기세포는 남성 불임치료 및 생식능력 향상을 위해서도 필수적인 연구부분으로 평가된다. On the other hand, in mammals, including humans, sperm, which is a germ cell, is an important vehicle for transmitting male genetic information to the next generation, and spermatogenesis, which involves a series of complex processes that produce sperm, preserves species It is an essential process for genetic diversity. In this complex and productive sperm formation process, germline stem cells, sperm stem cells, are recognized as important basic cells that maintain sperm formation throughout the life of men. In particular, sperm stem cells, which play a direct role in sperm production, are also considered as essential research areas for the treatment of male infertility and improvement of fertility.
지난 90년대부터 국내에서는 성기능 향상을 위해서 생약을 주 원료로 제조되는 기능성 보조제 위주의 연구가 활발히 수행되었다. 농촌진흥청이 개발하여 2001년부터 시판하고 있는 “누에그라”, 종근당이 옥타코사놀을 주성분으로 하여 정력증진용 건강보조식품으로 개발한 “롱타임F", 한국의과학연구소에서 개발한 성기능향상 한방 제품 ”천보204“, 한국인삼공사가 홍삼을 주 원료로 개발한 ”레드맥스“ 등 다양한 천연물 기반 제품들이 판매되고 있다.Since the 1990s, research on functional supplements made from herbal medicines as the main raw material has been actively conducted in Korea to improve sexual function. “Nugra” developed by the Rural Development Administration and marketed since 2001, “Long Time F” developed by Chong Kun Dang as a health supplement for stabilization with octacosanol as the main ingredient, and sexual enhancement medicine developed by the Korea Institute of Science and Technology. ” Various natural products based products such as Cheonbo 204 ”and“ Red Max ”developed by Korea Ginseng Corporation as the main raw material are sold.
그러나 남성의 정자 농도나 운동성, 정자 수의 증가를 향상시키는 의약 또는 식품이 개발되지 못한 상황이다.However, there are no medicines or foods to improve sperm concentration, mobility, and sperm count in men.
본 발명의 목적은 복합 천연물의 추출물을 유효성분으로 이용하여 남성의 정자농도, 정자 직진운동성, 총 움직이는 정자 수를 증가시켜, 남성 불임증 치료 및 예방용 약학적 조성물 및 건강기능성 식품 조성물을 제공하는데 있다.An object of the present invention is to provide a pharmaceutical composition and a health functional food composition for treating and preventing male infertility by increasing sperm concentration, sperm straightness, and total number of sperm in men by using an extract of a complex natural product as an active ingredient. .
상기와 같은 목적을 달성하기 위하여, 본 발명의 남성불임증의 예방 및 치료용 약학 조성물은 14가지 천연물로부터 선택되는 복합 추출물을 유효성분으로 함유하는 것을 특징으로 한다. In order to achieve the above object, the pharmaceutical composition for the prevention and treatment of male infertility of the present invention is characterized by containing a complex extract selected from 14 natural products as an active ingredient.
여기서, 상기 천연물은 토사자(Cuscutae Semen), 지황(Rehmanniae Radix Preparata), 음양곽(Epimedii Herba), 파극천(Morindae Radix), 쇄양(Cynomorii Herba), 산수유(Corni Fructus), 구기자(Lycii Fructus), 산약(Dioscoreae Rhizoma), 복분자(Rubi Fructus), 인삼(Ginseng Radix), 계피(Cinnamomi Cortex), 복령(Poria Sclerotium), 차전자(Plantaginis Semen) 및 오미자(Schisandrae Fructus)로 이루어진 군에서 선택되는 둘 이상의 복합 추출물을 유효성분으로 포함하는 것이 바람직하다.Here, the natural products include Cusaeae Semen, Rehmanniae Radix Preparata, Epimedii Herba, Morindae Radix, Cynomorii Herba, Cornus Fructus, Goji (Lycii Fructus) Two or more complex extracts selected from the group consisting of Dioscoreae Rhizoma, Rubi Fructus, Ginseng Radix, Cinnamomi Cortex, Poria Sclerotium, Plantaginis Semen and Schizandrae Fructus It is preferable to include as an active ingredient.
상기 남성 불임증은 무정자증, 감정자증, 약정자증 및 기형정자증에서 선택되는 하나 이상의 정자 관련 불임증인 것이 바람직하다. The male infertility is preferably one or more sperm-related infertility selected from azoospermia, empathy, contractorism and malformation spermosis.
또 다른 구체적인 예로, 상기 천연물을 모두 포함하는 경우 상기 복분자 10 중량부에 대하여, 토사자 12 중량부, 지황 12중량부, 음양곽 12 중량부, 파극천 10 중량부, 쇄양 10 중량부, 산수유 10 중량부, 구기자 10 중량부, 산약 10 중량부, 인삼 6 중량부, 계피 6중량부, 복령 6 중량부, 차전자 4 중량부 및 오미자 4 중량부로 혼합된 복합 추출물을 유효성분으로 제공한다.As another specific example, when all of the natural product is contained, 12 parts by weight of soil, 12 parts by weight of sulfur, 12 parts by weight of yin and yang, 12 parts by weight of Pagukcheon, 10 parts by weight of ginseng, 10 parts by weight of cornus, Gojija 10 parts by weight, 10 parts by weight of acid, 6 parts by weight of ginseng, 6 parts by weight of cinnamon, 6 parts by weight of Bokryeong, 4 parts by weight of tea and 4 parts by weight of Omija are provided as active ingredients.
한편, 본 발명의 남성불임증의 예방 및 개선용 건강기능식품은 상기 복합 추출물을 유효성분으로 함유하는 것을 특징으로 한다. Meanwhile, the health functional food for preventing and improving male infertility of the present invention is characterized by containing the complex extract as an active ingredient.
여기서, 상기 건강기능식품은 산제, 과립제, 정제, 캡슐제, 환제, 현탁액, 에멀젼, 시럽제, 티백제, 침출차 또는 건강 음료 형태 등인 것이 바람직하다. Here, the health functional food is preferably in the form of powder, granule, tablet, capsule, pill, suspension, emulsion, syrup, tea bag, leached tea or healthy beverage.
또한, 본 발명의 남성불임증의 예방 및 개선용 건강보조식품은 상기 복합 추출물을 유효성분으로 함유하는 것을 특징으로 한다. In addition, the health supplement for preventing and improving male infertility of the present invention is characterized by containing the complex extract as an active ingredient.
본 발명의 천연물의 복합 추출물은 남성의 정자 운동성을 증가시키고, 정자 수를 증가시킴으로써, 남성 불임증의 예방 및 치료를 위한 약학 조성물, 건강기능식품 및 건강보조식품에 유용하게 이용될 수 있는 효과가 있다.The complex extract of the natural product of the present invention increases the sperm motility of men and increases the number of sperm, and thus can be usefully used in pharmaceutical compositions, health functional foods and health supplements for the prevention and treatment of male infertility. .
본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 아니 되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다. The terms or words used in the specification and claims should not be interpreted as being limited to ordinary or lexical meanings, and the inventor can appropriately define the concept of terms in order to explain his or her invention in the best way. Based on the principle that it should be interpreted as meanings and concepts consistent with the technical spirit of the present invention.
본 발명의 남성 불임증 치료 및 예방용 약학 조성물은 상술한 바와 같은 목적을 달성하기 위하여 14가지 천연물로부터 선택되는 복합 추출물을 유효성분으로 함유하는 것을 특징으로 한다.The pharmaceutical composition for treating and preventing male infertility of the present invention is characterized by containing as an active ingredient a complex extract selected from 14 natural products in order to achieve the above-described object.
또한, 상기 천연물은 토사자(Cuscutae Semen), 지황(Rehmanniae Radix Preparata), 음양곽(Epimedii Herba), 파극천(Morindae Radix), 쇄양(Cynomorii Herba), 산수유(Corni Fructus), 구기자(Lycii Fructus), 산약(Dioscoreae Rhizoma), 복분자(Rubi Fructus), 인삼(Ginseng Radix), 계피(Cinnamomi Cortex), 복령(Poria Sclerotium), 차전자(Plantaginis Semen) 및 오미자(Schisandrae Fructus)로 이루어진 군에서 선택되는 둘 이상의 천연물이 혼합된 것을 추출할 수 있다.In addition, the natural products include Cusaeae Semen, Rehmanniae Radix Preparata, Epimedii Herba, Morindae Radix, Cynomorii Herba, Cornus Fructus, Goji (Lycii Fructus) Two or more natural products selected from the group consisting of Dioscoreae Rhizoma, Rubi Fructus, Ginseng Radix, Cinnamomi Cortex, Poria Sclerotium, Plantaginis Semen, and Schisandrae Fructus Mixed ones can be extracted.
또한, 상기 복합 추출물은 물, C1 내지 C4의 저급 알코올 또는 이들의 혼합용매로, 바람직하게는 물 또는 물 및 에탄올 혼합용매, 보다 바람직하게는 물 및 에탄올 혼합용매로 추출 할 수 있다.In addition, the complex extract may be extracted with water, a lower alcohol of C1 to C4, or a mixed solvent thereof, preferably a mixed solvent of water or water and ethanol, more preferably a mixed solvent of water and ethanol.
또한, 상기 복합 추출물은 정자 운동성 증가 효과를 가질 수 있다.In addition, the composite extract may have an effect of increasing sperm motility.
또한, 상기 복합 껍질 추출물은 정자수 증가 효과를 가질 수 있다.In addition, the composite shell extract may have an effect of increasing sperm count.
또한, 상기 남성불임증은 무정자증, 감정자증, 약정자증 및 기형정자 등을 포함하며, 바람직하게는, 정자와 관련된 모든 불임증을 포함한다.In addition, the male infertility includes azoospermia, empathy, contractor and malformed sperm, and preferably includes all infertility related to sperm.
한편, 본 발명의 남성불임증의 예방용 건강기능식품은 천연물의 복합 추출물을 유효성분으로 함유하는 것을 특징으로 한다.On the other hand, the health functional food for preventing male infertility of the present invention is characterized by containing a complex extract of natural products as an active ingredient.
이하, 본 발명을 상세히 설명한다. 본 발명의 복합 추출물은 하기와 같은 통상의 추출과정을 통하여 수득될 수 있다. Hereinafter, the present invention will be described in detail. The composite extract of the present invention can be obtained through the following general extraction process.
상기 천연물을 세척 후 추출을 위한 용매로서 물, C1 내지 C5의 저급알콜 또는 그 혼합물로 이루어진 군에서 선택하였다. The natural product was selected from the group consisting of water, C1 to C5 lower alcohol or a mixture thereof as a solvent for extraction after washing.
본 발명에 따른 남성불임증의 예방 및 치료용 약학 조성물은, 조성물 총 중량에 대하여 상기 추출물 0.1 내지 99 중량%를 포함한다.The pharmaceutical composition for preventing and treating male infertility according to the present invention includes 0.1 to 99% by weight of the extract based on the total weight of the composition.
본 발명의 복합 추출물을 포함하는 약학 조성물은 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical composition comprising the complex extract of the present invention may further include suitable carriers, excipients and diluents commonly used in the preparation of the composition.
본 발명의 추출물의 약학적 투여 형태는 이들의 약학적으로 허용 가능한 염의 형태로 사용될 수도 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수도 있다.The pharmaceutical dosage form of the extract of the present invention may be used in the form of their pharmaceutically acceptable salts, or may be used alone or in combination with other pharmaceutically active compounds, as well as in a suitable collection.
본 발명에 따른 추출물을 포함하는 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition comprising the extract according to the present invention is in the form of an oral dosage form such as powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, external preparation, suppository and sterile injectable solution, respectively, according to a conventional method. It can be formulated and used.
추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 및 광물유를 들 수 있다.Carriers, excipients and diluents that may be included in the composition comprising the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.In the case of formulation, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants.
경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 상기 추출물에 적어도 하나 이상의 부형제, 예를 들면 전분, 칼슘카보네이트 (calcium carbonate), 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다.Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations contain at least one excipient in the extract, for example starch, calcium carbonate, sucrose. Or it is prepared by mixing lactose, gelatin, and the like. In addition, lubricants such as magnesium stearate and talc are used in addition to simple excipients.
경구 투여를 위한 액상 제제로는 현탁액, 내용액제, 유제, 시럽제 등이 해당되는데, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Liquid preparations for oral administration include suspensions, intravenous solutions, emulsions, syrups, etc. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, can be included. have.
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수용성제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween), 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As the water-insoluble agent and the suspension agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween, cacao butter, laurin butter, and glycerogelatin may be used.
본 발명의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서 본 발명의 추출물은 1일 0.0001 내지 10 g/㎏, 바람직하게는 0.01 내지 1 g/㎏으로 투여되는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the extract of the present invention depends on the patient's condition and body weight, the degree of disease, the drug form, the route and duration of administration, but can be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 0.0001 to 10 g / kg per day, preferably 0.01 to 1 g / kg per day. The administration may be administered once a day, or may be divided into several times. The above dosage does not limit the scope of the present invention in any way.
본 발명은 또한 상기 복합 추출물을 포함하는 정자 운동 증진제를 제공하며, 이러한 정자 운동 증진제는 체외수정시 수정율을 향상시키기 위한 것이다. 본 발명은 또한 상기 출물을 포함하는 정자 운동 증진의 남성 불임 치료제로서 여성용 질정 및 질세정제, 그리고 질삽입제를 제공한다. 본 발명은 또한 체외수정시 수정율을 향상시키기 위하여 상기 추출물을 포함하는 체외수정용 정자보관용 첨가제를 제공한다.The present invention also provides a sperm exercise enhancer comprising the complex extract, and this sperm exercise enhancer is intended to improve fertilization rate during in vitro fertilization. The present invention also provides a vaginal and vaginal cleansing agent for women and vaginal inserts as a male fertility treatment agent for enhancing sperm movement including the extract. The present invention also provides an additive for sperm storage for in vitro fertilization containing the extract in order to improve fertilization rate during in vitro fertilization.
본 발명은 남성불임증의 예방 효과를 나타내는 상기 추출물 및 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 건강기능식품을 제공한다.The present invention provides a health functional food comprising the extract showing the preventive effect of male infertility and food additives acceptable food supplement.
복합 추출물을 첨가할 수 있는 건강기능식품으로는 예를 들어, 각종 일반식품류, 음료, 껌, 차, 비타민 복합제 등이 있다.Health functional foods to which complex extracts can be added include, for example, various general foods, beverages, gums, teas, and vitamin complexes.
또한, 상기 복합 추출물은 남성불임증의 예방 효과를 목적으로 식품 또는 음료에 첨가될 수 있다. 이때, 식품 또는 음료 중의 상기 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 기능성 음료 조성물은 100 g을 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다.In addition, the complex extract may be added to food or beverage for the purpose of preventing male infertility. At this time, the amount of the extract in the food or beverage can be added at 0.01 to 15% by weight of the total food weight, the health functional beverage composition is added at a rate of 0.02 to 5 g, preferably 0.3 to 1 g, based on 100 g Can be.
본 발명의 건강 기능성 음료 조성물은 필수 성분으로서 상기 명시된 함량범위의 상기 추출물을 함유하는 것 이외에 다른 성분에는 특별한 제한이 없으며, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등의 추가 성분을 더 함유할 수 있다. The health functional beverage composition of the present invention is an essential component other than containing the extract in the above-mentioned content range, there is no particular limitation, and further contains various components such as various flavoring agents or natural carbohydrates, such as ordinary beverages. can do.
상술한 천연 탄수화물의 예로는 모노사카라이드, 예를 들어 포도당, 과당 등; 디사카라이드, 예를 들어 말토오스, 수크로오스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 솔비톨, 에리스리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제인 타우마틴, 스테비아 추출물, 예를 들어 레바우디오시드 A, 글리시르히진 등; 및 합성 향미제, 예를 들어 사카린, 아스파르탐 등을 유리하게 사용할 수 있다. 상기 천연 탄수화물의 함량은 본 발명의 조성물 100 g당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose, etc .; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents such as taumatin, stevia extract, for example rebaudioside A, glycyrrhizine, etc .; And synthetic flavoring agents, such as saccharin, aspartame, and the like. The content of the natural carbohydrate is generally about 1 to 20 g per 100 g of the composition of the present invention, preferably about 5 to 12 g.
상기 외에 본 발명의 추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 및 천연 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. In addition to the above, the extract of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and neutralizers (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective properties It may contain colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages, and the like.
그밖에 본 발명의 추출물들은 천연 과일 주스, 과일 주스 음료 및 야채 음료의 제조를 위한 과육 등을 함유할 수 있다. 이러한 성분들은 독립적으로 또는 조합하여 사용할 수 있다. 이때, 첨가제의 비율은 그다지 중요하지는 않지만 본 발명의 추출물 100 중량부 당 0.01 내지 약 20 중량부의 범위에서 선택되는 것이 바람직하다.In addition, the extracts of the present invention may contain natural fruit juice, fruit juice beverage, fruit flesh for the production of vegetable beverages, and the like. These ingredients can be used independently or in combination. At this time, the proportion of the additive is not very important, but preferably selected from the range of 0.01 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.
이하, 본 발명의 바람직한 실시예에 대하여 상세히 설명한다. 또한, 하기의 설명에서는 구체적인 구성요소 등과 같은 많은 특정사항들이 설명되어 있는데, 이는 본 발명의 보다 전반적인 이해를 돕기 위해서 제공된 것일 뿐 이러한 특정 사항들 없이도 본 발명이 실시될 수 있음은 이 기술분야에서 통상의 지식을 가진 자에게는 자명하다 할 것이다. 그리고, 본 발명을 설명함에 있어서, 관련된 공지 기능 혹은 구성에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.Hereinafter, preferred embodiments of the present invention will be described in detail. In addition, in the following description, many specific matters such as specific components are described, which are provided to help a more comprehensive understanding of the present invention, and it is common in the art that the present invention can be practiced without these specific details. It will be obvious to those who have the knowledge of. And, in the description of the present invention, when it is determined that a detailed description of a related known function or configuration may unnecessarily obscure the subject matter of the present invention, the detailed description will be omitted.
실시예Example
토사자 12g, 지황 12 g, 음양곽 12 g, 파극천 10 g, 쇄양 10 g, 산수유 10 g, 구기자 10 g, 산약 10 g, 인삼 6 g, 계피 6 g, 복령 6 g, 차전자 4 g, 복분자 10 g 및 오미자 4 g을 물 3ℓ를 넣고 환류 냉각 하면서 2시간 2회 반복하여 추출한 후, 여과하고 감압 조건하에서 농축하였다. 농축된 여과물은 감압 조건하에서 냉동 건조기로 동결 건조하여 추출물 분말을 얻어 4℃에서 보관하였다. 실험에 사용하기 전, 건조된 추출물을 생리식염수에 녹이고 실온에서 2분간 격렬하게 섞었다. 12 g of sediment, 12 g of sulcus, 12 g of yin and yang gu, 10 g of ginseng, 10 g of ginseng, 10 g of cornus officinalis, 10 g of goji wolfberry, 10 g of wild medicine, 6 g of ginseng, 6 g of cinnamon, 6 g of bokyeong, 4 g of tea roaster, 4 g g and 4 g of Omija were added 3 liters of water, extracted repeatedly with reflux cooling for 2 hours, and then filtered and concentrated under reduced pressure. The concentrated filtrate was freeze-dried with a freeze dryer under reduced pressure to obtain an extract powder and stored at 4 ° C. Before use in the experiment, the dried extract was dissolved in physiological saline and mixed vigorously at room temperature for 2 minutes.
시험예Test example
상기 실시예의 시료에 대하여 사람정액의 정자수와 운동성 변화에 미치는 영향을 알아보기 위하여 정자 운동 증진 효능 평가법을 이용하여 실험을 수행하였다. 정액검사 소견이 이상이 있는 16명의 남성난임 환자를 대상으로 상기 열수추출물(120cc)을 하루 2회 식후에 따뜻하게 하여 10주 동안 복용하게 하였다. For the samples of the above examples, experiments were conducted using the sperm movement enhancement efficacy evaluation method to find out the effect on the sperm count and motility change of human sperm. The hot water extract (120cc) was warmed twice a day after eating for 10 weeks in 16 male infertility patients with abnormal semen test findings.
상기 복합 추출물을 복용 10주 후 정액검사를 재시행하여 치료 전 정액검사 소견과 비교하였다. 10주 동안의 복합 추출물 처치 결과, 정자 농도, 정자의 직진 운동성, 총 움직이는 정자 수가 유의하게 증가됨을 확인하였다The semen test was re-executed 10 weeks after taking the complex extract and compared with the pre-treatment semen test findings. As a result of treatment with the complex extract for 10 weeks, it was confirmed that sperm concentration, sperm straight motility, and total sperm count increased significantly.
<10주간 한약(KHM) 투여 후 정자 지표들의 변화><Changes of sperm indicators after 10 weeks of herbal medicine (KHM) administration>
(10 weeks) (n=16)Post-KHM treatment
(10 weeks) (n = 16)
2.25 (1.53, 2.98)
(×106/ml)Sperm concentration
(× 10 6 / ml)
(×106)Total motile sperm count
(× 10 6 )
* 데이터는 하위 및 상위 사 분위와 함께 중간값으로 표시됨.* Data is displayed as median with lower and upper quartiles.
데이터는 평균 ± 표준편차로 표시됨 Data are expressed as mean ± standard deviation
아래에 본 발명의 추출물을 포함하는 약학 조성물 및 건강기능식품의 제제예를 설명하나, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, a pharmaceutical composition containing the extract of the present invention and a formulation example of a health functional food will be described, but this is not intended to limit the present invention, but only to be specifically described.
제제예 1 : 산제의 제조Formulation Example 1: Preparation of powder
복합 추출물 분말 20 ㎎Complex extract powder 20 mg
유당 100 ㎎Lactose 100 mg
탈크 10 ㎎Talc 10 mg
상기의 성분들을 혼합하고, 기밀포에 충진하여 산제를 제조하였다.The above ingredients were mixed and filled in an airtight fabric to prepare a powder.
제제예 2 : 정제의 제조Formulation Example 2: Preparation of tablets
복합 추출물 분말 10 ㎎Complex extract powder 10 mg
*옥수수 전분 100 ㎎* 100 mg corn starch
유당 100 ㎎Lactose 100 mg
스테아린산 마그네슘 2 ㎎Magnesium stearate 2mg
상기의 성분들을 혼합한 후 통상의 정제 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional tablet manufacturing method.
제제예 3 : 캅셀제의 제조Formulation Example 3: Preparation of capsules
복합 추출물 분말 10 ㎎Complex extract powder 10 mg
결정성 셀룰로오스 3 ㎎Crystalline cellulose 3 mg
락토오스 14.8 ㎎Lactose 14.8 mg
마그네슘 스테아레이트 2 ㎎Magnesium stearate 2mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.The above ingredients were mixed and filled in gelatin capsules according to a conventional capsule preparation method to prepare capsules.
제제예 4 : 주사제의 제조Formulation Example 4: Preparation of Injection
복합 추출물 분말 10 ㎎Complex extract powder 10 mg
만니톨 180 ㎎Mannitol 180 mg
주사용 멸균 증류수 2794 ㎎Sterile distilled water for injection 2794 mg
Na2HPO412H2O 26 ㎎Na2HPO412H2O 26 mg
통상의 주사제 제조방법에 따라 1 앰플 (2 ㎖)당 상기의 성분 함량으로 제조하였다.It was prepared with the above ingredient content per ampoule (2 ml) according to a conventional injection preparation method.
제제예 5 : 액제의 제조Formulation Example 5: Preparation of liquid formulation
복합 추출물 분말 10 ㎎Complex extract powder 10 mg
이성화당 10 gIsomerized sugar 10 g
만니톨 5 g5 g mannitol
정제수 적당량An appropriate amount of purified water
통상의 액제 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고, 레몬향을 적당량 가한 다음 상기의 성분을 혼합한 후 정제수를 가하여 전체를 100 ㎖로 조절하고 갈색병에 충진하여 멸균시켜 액제를 제조하였다.Each component is added and dissolved in purified water according to a conventional liquid preparation method, a suitable amount of lemon scent is added, and the above components are mixed, and then purified water is added to adjust the total to 100 ml and sterilized by filling in a brown bottle. Did.
제제예 6 : 건강 음료의 제조Formulation Example 6: Preparation of healthy drinks
복합 추출물 분말 10 ㎎Complex extract powder 10 mg
비타민 C 15 gVitamin C 15 g
비타민 E(분말) 100 gVitamin E (powder) 100 g
젖산철 19.75 gIron lactate 19.75 g
산화아연 3.5 gZinc oxide 3.5 g
니코틴산아미드 3.5 gNicotinic acid amide 3.5 g
비타민 A 0.2 gVitamin A 0.2 g
비타민 B1 0.25 gVitamin B1 0.25 g
비타민 B2 0.3 gVitamin B2 0.3 g
물 적당량An appropriate amount of water
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 ℃에서 교반 가열 후, 만들어진 용액을 여과하고 멸균된 2 ℓ의 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관하여 본 발명에 따른 건강음료 조성물 제조에 사용하였다. 상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층이나 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.After mixing the above components according to a conventional health drink manufacturing method, after stirring and heating at 85 ° C. for about 1 hour, the resulting solution is filtered, obtained in a sterilized 2 liter container, sealed and sterilized, and stored in the refrigerator for refrigeration. It was used to prepare a health drink composition according to. Although the above composition ratio is a mixture of components suitable for a preference drink in a preferred embodiment, the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, country of demand, and usage.
이상에서는 본 발명의 바람직한 실시예에 대해서 설명하였으나, 본 발명은 상술한 특정의 실시예에 한정되지 아니하며, 당해 기술분야에서 통상의 지식을 가진 자라면 본원 발명의 요지를 벗어남이 없이 다양한 변형 실시가 가능함은 물론이다. 따라서, 본 발명의 범위는 위의 실시예에 국한해서 해석되어서는 안되며, 후술하는 특허청구범위 뿐만 아니라 이 특허청구범위와 균등한 것들에 의해 정해져야 할 것이다.The preferred embodiments of the present invention have been described above, but the present invention is not limited to the specific embodiments described above, and those skilled in the art can perform various modifications without departing from the gist of the present invention. Of course it is possible. Therefore, the scope of the present invention should not be construed as being limited to the above embodiment, but should be defined by the claims and equivalents as well as the claims below.
Claims (6)
Cuscutae Semen, Rehmanniae Radix Preparata, Epimedii Herba, Morindae Radix, Cynomorii Herba, Corni Fructus, Goji (Lycii Fructus), Wild Medicine (Dioscoreae Rhizoma) (Rubi Fructus), Ginseng (Ginseng Radix), Cinnamon (Cinnamomi Cortex), Bokryeong (Poria Sclerotium), Chajeon (Plantaginis Semen) and Omija (Schisandrae Fructus) selected from the group consisting of a mixture of two or more natural extracts mixed Pharmaceutical composition for the prevention and treatment of male infertility, including as an active ingredient.
The pharmaceutical composition for preventing and treating male infertility according to claim 1, wherein the male infertility is at least one sperm-related infertility selected from azoospermia, sperm reduction, contractile sperm and malformed spermosis.
The method of claim 1, wherein the complex extract is 100 parts by weight, 12 parts by weight of soil, 12 parts by weight of sulfur, 12 parts by weight of yin and yang, 10 parts by weight of gyeokyang, 10 parts by weight of ginseng, 10 parts by weight of cornflower, 10 parts by weight of goji berries , 10 parts by weight of acid powder, 10 parts by weight of bokbunja, 6 parts by weight of ginseng, 6 parts by weight of cinnamon, 6 parts by weight of boknyeong, 4 parts by weight of tea roaster and 4 parts by weight of Omija
Lion (Cuscutae Semen), Rehmanniae Radix Preparata, Epimedii Herba, Morindae Radix, Cynomorii Herba, Corni Fructus, Wolfberry (Lycii Fructus), Wild Medicine (Dioscoreae Rhizoma) (Rubi Fructus), Ginseng (Ginseng Radix), Cinnamon (Cinnamomi Cortex), Bokryeong (Poria Sclerotium), Chajeon (Plantaginis Semen) and Omija (Schisandrae Fructus) selected from the group consisting of a mixture of two or more natural extracts mixed A health supplement for improving male infertility, which is included as an active ingredient.
상기 건강기능식품은 산제, 과립제, 정제, 캡슐제, 환제, 현탁액, 에멀젼, 시럽제, 티백제, 침출차 또는 건강 음료 형태인 것을 특징으로 하는 건강기능성 식품 조성물.
In the fourth,
The health functional food is a health functional food composition characterized in that it is in the form of powder, granule, tablet, capsule, pill, suspension, emulsion, syrup, tea bag, leach tea or healthy beverage.
Lion (Cuscutae Semen), Rehmanniae Radix Preparata, Epimedii Herba, Morindae Radix, Cynomorii Herba, Corni Fructus, Wolfberry (Lycii Fructus), Wild Medicine (Dioscoreae Rhizoma) (Rubi Fructus), Ginseng (Ginseng Radix), Cinnamon (Cinnamomi Cortex), Bokryeong (Poria Sclerotium), Chajeon (Plantaginis Semen) and Omija (Schisandrae Fructus) selected from the group consisting of a mixture of two or more natural extracts mixed A health supplement for improving male infertility, characterized by containing as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180143651A KR20200058929A (en) | 2018-11-20 | 2018-11-20 | A composition comprising an extract of combined natural products for treating and preventing Male Infertility |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180143651A KR20200058929A (en) | 2018-11-20 | 2018-11-20 | A composition comprising an extract of combined natural products for treating and preventing Male Infertility |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20200058929A true KR20200058929A (en) | 2020-05-28 |
Family
ID=70920324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180143651A KR20200058929A (en) | 2018-11-20 | 2018-11-20 | A composition comprising an extract of combined natural products for treating and preventing Male Infertility |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20200058929A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070094394A (en) | 2006-03-17 | 2007-09-20 | 서울향료(주) | A composition comprising medical herbs for infertility |
KR101751211B1 (en) | 2014-12-17 | 2017-06-28 | 홍상근 | Composition for improving sexual function, Functional food Composition for improving sexual function comprising of the same and Manufacturing method thereof |
-
2018
- 2018-11-20 KR KR1020180143651A patent/KR20200058929A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070094394A (en) | 2006-03-17 | 2007-09-20 | 서울향료(주) | A composition comprising medical herbs for infertility |
KR101751211B1 (en) | 2014-12-17 | 2017-06-28 | 홍상근 | Composition for improving sexual function, Functional food Composition for improving sexual function comprising of the same and Manufacturing method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190328817A1 (en) | Traditional chinese medicine healthcare preparation for fat elimination and weight reduction | |
KR102262306B1 (en) | Composition for relieving premenstrual syndrome and menstrual pain | |
KR100597235B1 (en) | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis | |
KR20140108942A (en) | Composition of herbal medicine for improving implantation | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR20050114929A (en) | Composition for treating and preventing constipation | |
KR102366919B1 (en) | Functional health food composition for inhibiting muscle reduction comprising a mixed extract of mulberry twig, Eucommia bark, Acanthopanax, and black bean | |
KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
KR20200014566A (en) | A composition for improving, preventing and treating of arthritis comprising Milk thistle and Achyranthes bidentata Blume | |
KR102410771B1 (en) | Composition for preventing or treating sarcopenia comprising blueberry extract | |
KR20200058929A (en) | A composition comprising an extract of combined natural products for treating and preventing Male Infertility | |
CN113456778A (en) | Composition for improving energy and preparation method thereof | |
KR101479096B1 (en) | Health functional food comprising extracts of herbal mixture for preventing or improving edema of delivered or pregnant woman | |
KR101456127B1 (en) | A composition for increasing bone growth | |
KR20110030875A (en) | A composition for preventing and treating bone diseases comprising the extract of herbal medicine | |
KR100888068B1 (en) | Compositions for suppressing obesity | |
KR101787458B1 (en) | Composition comprising extract of Myristica fragrans Houtt for treating or preventing endometriosis | |
CN104474337A (en) | Preparation method of Chinese patent health granule containing green tea extract | |
KR20170130082A (en) | A Composition Comprising the root extract of Achyranthes japonica NAKAI for preventing or improving the hormonal abnormal syndrome in women | |
CN101190249B (en) | Composition for preventing and controlling high-altitude disease and preparation method thereof | |
KR101801130B1 (en) | A Composition Comprising the combined herbal extract for preventing or improving the hormonal abnormal syndrome in women | |
KR20170101489A (en) | Composition for preventing, improving or treating disease caused by side effect of anticancer agent comprising Cistanchis Herba extract as effective component | |
KR20190074104A (en) | Composition for preventing, improving or treating of andropause syndrome or, for improving sperm mobility comprising premature black raspberry extract | |
KR20160001392A (en) | Composition comprising the combined extracts of Phlomis umbrosa, Astragalus membranceus, Discorea japonica, Acanthpanax senticosus and Angelica gigas for stimulating bone growth |